Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 1
1997 1
1998 1
2005 1
2008 1
2014 3
2015 1
2016 2
2017 1
2018 1
2019 1
2020 2
2021 2
2022 2
2023 3
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

25 results

Results by year

Filters applied: . Clear all
Page 1
Alirocumab and Coronary Atherosclerosis in Asymptomatic Patients with Familial Hypercholesterolemia: The ARCHITECT Study.
Pérez de Isla L, Díaz-Díaz JL, Romero MJ, Muñiz-Grijalvo O, Mediavilla JD, Argüeso R, Sánchez Muñoz-Torrero JF, Rubio P, Álvarez-Baños P, Ponte P, Mañas D, Suárez Gutierrez L, Cepeda JM, Casañas M, Fuentes F, Guijarro C, Ángel Barba M, Saltijeral Cerezo A, Padró T, Mata P; SAFEHEART Study Group. Pérez de Isla L, et al. Among authors: argueso r. Circulation. 2023 May 9;147(19):1436-1443. doi: 10.1161/CIRCULATIONAHA.122.062557. Epub 2023 Apr 3. Circulation. 2023. PMID: 37009731 Free PMC article.
Familial Hypercholesterolemia and Lipoprotein(a): Two Partners in Crime?
Alonso R, Argüeso R, Álvarez-Baños P, Muñiz-Grijalvo O, Diaz-Diaz JL, Mata P. Alonso R, et al. Among authors: argueso r. Curr Atheroscler Rep. 2022 Jun;24(6):427-434. doi: 10.1007/s11883-022-01019-5. Epub 2022 Apr 7. Curr Atheroscler Rep. 2022. PMID: 35386090 Review.
Comments on the 2019 ESC/EAS guidelines for the management of dyslipidemias.
SEC Working Group for the 2019 ESC EAS guidelines for the management of dyslipidaemias, Expert Reviewers for the 2019 ESC guidelines for the management of dyslipidaemias, SEC Guidelines Committe; Grupo de Trabajo de la SEC para la guía ESC 2019 sobre el tratamiento de las dislipemias; Revisores expertos para la ESC 2019 sobre el tratamiento de las dislipemias; Comité de Guías de la SEC. SEC Working Group for the 2019 ESC EAS guidelines for the management of dyslipidaemias, Expert Reviewers for the 2019 ESC guidelines for the management of dyslipidaemias, SEC Guidelines Committe, et al. Rev Esp Cardiol (Engl Ed). 2020 May;73(5):348-353. doi: 10.1016/j.rec.2019.11.019. Epub 2020 Mar 21. Rev Esp Cardiol (Engl Ed). 2020. PMID: 32205101 English, Spanish. No abstract available.
[Familial combined hyperlipidemia: consensus document].
Mata P, Alonso R, Ruíz-Garcia A, Díaz-Díaz JL, González N, Gijón-Conde T, Martínez-Faedo C, Morón I, Arranz E, Aguado R, Argueso R, Perez de Isla L. Mata P, et al. Among authors: argueso r. Aten Primaria. 2014 Oct;46(8):440-6. doi: 10.1016/j.aprim.2014.04.013. Epub 2014 Jul 14. Aten Primaria. 2014. PMID: 25034722 Free PMC article. Spanish.
Characteristics of Coronary Atherosclerosis Related to Plaque Burden Regression During Treatment With Alirocumab: The ARCHITECT Study.
Pérez de Isla L, Díaz-Díaz JL, Romero MJ, Muñiz-Grijalvo O, Mediavilla JD, Argüeso R, de Andrés R, Fuentes F, Sánchez Muñoz-Torrero JF, Rubio P, Álvarez-Baños P, Mañas D, Suárez Gutierrez L, Saltijeral Cerezo A, Mata P; SAFEHEART Investigators. Pérez de Isla L, et al. Among authors: argueso r. Circ Cardiovasc Imaging. 2024 Jan;17(1):e016206. doi: 10.1161/CIRCIMAGING.123.016206. Epub 2024 Jan 11. Circ Cardiovasc Imaging. 2024. PMID: 38205656
[Familial combined hyperlipidemia: consensus document].
Mata P, Alonso R, Ruíz-Garcia A, Díaz-Díaz JL, González N, Gijón-Conde T, Martínez-Faedo C, Morón I, Arranz E, Aguado R, Argueso R, Perez de Isla L. Mata P, et al. Among authors: argueso r. Semergen. 2014 Oct;40(7):374-80. doi: 10.1016/j.semerg.2014.07.007. Epub 2014 Aug 11. Semergen. 2014. PMID: 25131181 Spanish.
Improved lipid-lowering treatment and reduction in cardiovascular disease burden in homozygous familial hypercholesterolemia: The SAFEHEART follow-up study.
Alonso R, Arroyo-Olivares R, Díaz-Díaz JL, Fuentes-Jiménez F, Arrieta F, de Andrés R, Gonzalez-Bustos P, Argueso R, Martin-Ordiales M, Martinez-Faedo C, Illán F, Saenz P, Donate JM, Sanchez Muñoz-Torrero JF, Martinez-Hervas S, Mata P. Alonso R, et al. Among authors: argueso r. Atherosclerosis. 2024 Mar 16:117516. doi: 10.1016/j.atherosclerosis.2024.117516. Online ahead of print. Atherosclerosis. 2024. PMID: 38523000 Free article.
Efficacy of PCSK9 inhibitors in the treatment of heterozygous familial hypercholesterolemia: A clinical practice experience.
Alonso R, Muñiz-Grijalvo O, Díaz-Díaz JL, Zambón D, de Andrés R, Arroyo-Olivares R, Fuentes-Jimenez F, Muñoz-Torrero JS, Cepeda J, Aguado R, Alvarez-Baños P, Casañas M, Dieguez M, Mañas MD, Rubio P, Argueso R, Arrieta F, Gonzalez-Bustos P, Perez-Isla L, Mata P; SAFEHEART investigators. Alonso R, et al. Among authors: argueso r. J Clin Lipidol. 2021 Jul-Aug;15(4):584-592. doi: 10.1016/j.jacl.2021.04.011. Epub 2021 May 7. J Clin Lipidol. 2021. PMID: 34052174
The Added Value of Coronary Calcium Score in Predicting Cardiovascular Events in Familial Hypercholesterolemia.
Gallo A, Pérez de Isla L, Charrière S, Vimont A, Alonso R, Muñiz-Grijalvo O, Díaz-Díaz JL, Zambón D, Moulin P, Bruckert E, Mata P, Béliard S; REFERCHOL and SAFEHEART Investigators. Gallo A, et al. JACC Cardiovasc Imaging. 2021 Dec;14(12):2414-2424. doi: 10.1016/j.jcmg.2021.06.011. Epub 2021 Jul 14. JACC Cardiovasc Imaging. 2021. PMID: 34274263 Free article.
25 results